Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma

Sakuma,Kaname; Tamura,Ryuki; Hanyu,Shintaro; Takahashi,Haruka; Sato,Hideaki; Oneyama,Takahiro; Yamaguchi,Akira; Tanaka,Akira

doi:10.3892/mco.2017.1459

Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma

Authors:
- Kaname Sakuma
- Ryuki Tamura
- Shintaro Hanyu
- Haruka Takahashi
- Hideaki Sato
- Takahiro Oneyama
- Akira Yamaguchi
- Akira Tanaka
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Niigata Hospital, The Nippon Dental University, Niigata, Niigata 951‑8580, Japan, Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Niigata 951‑8580, Japan
Published online on: October 18, 2017 https://doi.org/10.3892/mco.2017.1459
Pages: 1021-1026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Using trace three‑dimensional culture, the collagen gel droplet‑embedded culture drug sensitivity test (CD‑DST) can be tested even in cases with a small number of cells, including oral squamous cell carcinoma (OSCC), and evaluation of the antitumor effect with a drug concentration close to the in vivo level is possible. The present report aimed to evaluate the utility of the CD‑DST in the assessment of the in vitro efficacy of single‑agent and multidrug combination chemotherapy for OSCC in comparison with the clinical response rates and to examine the possible clinical application of CD‑DST for such cases. A total of 33 OSCC patients from whom 33 samples were obtained from January 2010 to September 2015 were included. CD‑DST was performed, individually and in combination, on the three drugs [i.e., cisplatin (CDDP), 5‑fluorouracil (5‑FU), and docetaxel (DOC)] and on super selective intra‑arterial infusion chemoradiotherapy (IACRT). The overall evaluable rate of the CD‑DST in OSCC was 81.8% (27 of 33 cases) and the sensitivity to each anticancer drug was evaluated. The in vitro efficacy rates of IACRT, cisplatin + 5‑fluorouracil, and docetaxel + cisplatin + 5‑fluorouracil (TPF) confirmed the estimated clinical response rates. In 14 of 33 patients, the results of CD‑DST were compared with clinical efficacy, which was judged based on measurable lesions on imaging. For TPF therapy, the sensitivity test of the IACRT had a positive predictive value of 90.9% (10 of 11 cases) and a negative predictive value of 100% (3 of 3 cases); the accuracy of the susceptibility test for the anticancer agents was 92.8% (13 of 14 cases). The CD‑DST may be useful in selecting multidrug combination chemotherapy and IACRT for OSCC, however, accumulation of further clinical data is required in the future.

View Figures

View References

1	Umeda M, Komatsubara H, Ojima Y, Minamikawa T, Shigeta T, Shibuya Y, Yokoo S and Komori T: Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU). Kobe J Med Sci. 50:189–196. 2004.PubMed/NCBI
2	Katori H, Tsukuda M, Mochimatu I, Ishitoya J, Kawai S, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Ikeda Y, et al: Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer. 90:348–352. 2004. View Article : Google Scholar : PubMed/NCBI
3	Ahn JS, Cho SH, Kim OK, Lee JK, Yang DH, Kim YK, Lee JJ, Lim SC, Kim HJ, Chung WK and Chung IJ: The efficacy of an induction chemotherapy combination with docetaxel, cisplatin and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. Cancer Res Treat. 39:93–98. 2007. View Article : Google Scholar : PubMed/NCBI
4	Fuwa N, Ito Y, Matsumoto A, Kamata M, Kodaira T, Furutani K, Sasaoka M, Kimura Y and Morita K: A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer. 89:2099–2105. 2000. View Article : Google Scholar : PubMed/NCBI
5	Kobayashi H, Tanisaka K, Kondo N, Mito Y, Koezuka M, Yokouchi H, Higashiyama M, Kodama K, Doi O, Yamada M, et al: Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness. Gan To Kagaku Ryoho. 22:1933–1939. 1995.(In Japanese). PubMed/NCBI
6	Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, et al: An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol. 11:449–455. 1997.PubMed/NCBI
7	Naitoh H, Yamamoto H, Murata S, Kobayashi H, Inoue K and Tani T: Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer. Gastric Cancer. 17:630–637. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, et al: Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett. 4:621–624. 2012.PubMed/NCBI
9	Mekata E, Sonoda H, Shimizu T, Tatsuta T, Yamaguchi T, Endo Y and Tani T: Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II–III colorectal cancer. Mol Clin Oncol. 1:763–767. 2013. View Article : Google Scholar : PubMed/NCBI
10	Sakuma K, Tanaka A and Mataga I: Collagen gel droplet-embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil. Oncol Lett. 12:4643–4650. 2016.PubMed/NCBI
11	Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer. 98:450–455. 2002. View Article : Google Scholar : PubMed/NCBI
12	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
13	Inuyama Y and Takeda C: A cooperative phase II study of cisplatin in patients with head and neck cancer. Gan To Kagaku Ryoho. 13:232–238. 1986.(In Japanese). PubMed/NCBI
14	Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 10:257–263. 1992. View Article : Google Scholar : PubMed/NCBI
15	Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, Konno A, Ebihara S, Sasaki Y, Kida A, et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho. 26:107–116. 1999.(In Japanese). PubMed/NCBI
16	Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai Y, et al: Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 31:744–751. 2013. View Article : Google Scholar : PubMed/NCBI
17	Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H and Ohtsu A: Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. Jpn J Clin Oncol. 39:225–230. 2009. View Article : Google Scholar : PubMed/NCBI
19	Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E and Fu K: Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: Results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 23:1447–1454. 2005. View Article : Google Scholar : PubMed/NCBI
20	Robbins KT, Kumar P, Regine WF, Wong FS, Weir AB III, Flick P, Kun LE, Palmer R, Murry T, Fontanesi J, et al: Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: The memphis experience. Int J Radiat Oncol Biol Phys. 38:263–271. 1997. View Article : Google Scholar : PubMed/NCBI
21	Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
22	Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
23	Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS and Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 298:1321–1327. 1978. View Article : Google Scholar : PubMed/NCBI
24	Kondo T, Lmamura T and Lchibashi H: In vitro test for sensitivity of tumor to carcinostatic agents. Gan. 57:113–121. 1966.PubMed/NCBI
25	Inaba M, Tashiro T, Sato S, Ohnishi Y, Tanisaka K, Kobayashi H and Koezuka M: In vitro-in vivo correlation in anticancer drug sensitivity test AUC-based concentrations and collagen gel droplet embedded culture. Oncology. 53:250–257. 1996. View Article : Google Scholar : PubMed/NCBI
26	Araki Y, Isomoto H, Matsumoto A, Kaibara A, Yasunaga M, Hayashi K, Yatsugi H and Yamauchi K: An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. Kurume Med J. 46:163–166. 1999. View Article : Google Scholar : PubMed/NCBI
27	Kawamura M, Inoue Y, Oyama T and Kobayashi K: Chemosensitivity test for uresectable non-small cell lung cancer. Nihon Geka Gakkai Zasshi. 103:229–232. 2002.(In Japanese). PubMed/NCBI
28	Yamamoto Y, Watanabe Y, Ishida N, Hidaka T, Sugishita H, Yoshida M, Yukumi S, Sato K, Nakagawa H, Horiuchi A and Kawachi K: Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer. Gan To Kagaku Ryoho. 35:793–796. 2008.PubMed/NCBI
29	Nakagawa T, Takahashi H, Kamiyama T, Nakanishi K, Takahashi M, Watanabe K, Taguchi K, Tsukahara M, Nakajima H, Kamachi H, et al: In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures. Gan To Kagaku Ryoho. 31:2145–2149. 2004.(In Japanese). PubMed/NCBI
30	Suzuki M, Ishikawa H, Tanaka A and Mataga I: Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue. Hum Cell. 24:21–29. 2011. View Article : Google Scholar : PubMed/NCBI